A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A

Registry ID

BO45887

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

HOFFMANN-LA ROCHE LIMITED

Start date

2026-07-28

Last update

2026-03-18

Conditions

• HEMOPHILIA A

Related clinical trials

• AN OPEN-LABEL, PARALLEL, PHASE 3, TWO-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FITUSIRAN PROPHYLAXIS IN MALE PARTICIPANTS AGED 1 TO LESS THAN 12 YEARS WITH HEMOPHILIA A OR B WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTORS VIII OR IX
• SYNOVIIIUS: PROSPECTIVE INTERVENTIONAL STUDY OF EFFECTIVENESS OF EFANESOCTOCOG ALFA PROPHYLAXIS ON SYNOVIAL HYPERTROPHY IN PATIENTS WITH HEMOPHILIA A
• OPEN-LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF MIM8 IN PARTICIPANTS WITH HAEMOPHILIA A WITH OR WITHOUT INHIBITORS
• A PHASE I/II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF NXT007 IN PERSONS WITH SEVERE OR MODERATE HEMOPHILIA A
• OPEN-LABEL SAFETY STUDY IN ADULTS AND ADOLESCENTS WITH HAEMOPHILIA A WITH AND WITHOUT FVIII INHIBITORS SWITCHING DIRECTLY FROM EMICIZUMAB PROPHYLAXIS TO NNC0365-3769 (MIM8) PROPHYLAXIS
• AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY <=2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS

View on source registry